Viking Therapeutics Inc Stock

Shares in Vikinig Therapeutics (NASDAQ: VKTX) rose by 16.5% in February, according to data from S&P Global Market Intelligence. The move helped the stock recover in 2026, and at the time of writing,

Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst.

In the 1990s, a group of research analysts worked at a prominent hedge fund, Tiger Management, led by the legendary investor Julian Robertson. After Tiger closed down, many of these analysts went on

Investors look to the recent moves of billionaires for one clear reason: They've demonstrated their knowledge of the stock market by choosing many winning investments over the years. But how do we

If you're looking to capitalize on the rapidly growing market for weight loss drugs, you can do so in different ways. One strategy is to invest in companies like Eli Lilly or Novo Nordisk that

If you're looking for the company-specific headline that sent shares of Viking Therapeutics (NASDAQ: VKTX) soaring today, don't bother. You won't find one. Rather, investors are proverbially

The weight loss drug market has been one key focus for investors in recent years. This is because demand has been incredibly high, driving blockbuster revenue for companies making such products --

Most veteran investors can attest that, although they're also often a complete bust, every now and then a biopharma stock dishes out a windfall gain.

That's what the analyst community seems to

Viking Therapeutics (NASDAQ: VKTX) is aiming to join one of the biggest growth industries of the times: the weight loss drug market. People hoping to lose weight have rushed to get in on GLP-1

When most people think about GLP-1 drugs, they think of the blockbuster products sold by pharma giants Eli Lilly and Novo Nordisk. Lilly makes Mounjaro and Zepbound, while Novo makes Ozempic and

Eli Lilly (NYSE: LLY) has crushed the market over the past decade, largely thanks to breakthroughs within its core therapeutic area. Some might think it's too late to invest in the stock. Eli Lilly

Royal Caribbean (NYSE: RCL) is set to launch a river cruise business through its upscale Celebrity brand, and demand has been so strong that the cruise line doubled its expected fleet size from 10

Obesity is a global health crisis and is a direct or indirect cause of various health conditions. The emergence of GLP-1 agonists over the past several years has ignited one of the most significant

Looking to beat the market over the next five years? Here's one strategy to adopt: Invest in stocks that have not performed well recently but boast attractive prospects.

Two intriguing corporations

Pharmaceutical giant Eli Lilly (NYSE: LLY) and biotech Viking Therapeutics (NASDAQ: VKTX) have one major thing in common: They both work in the high-growth area of weight loss drugs. Lilly's

Last year was a challenging one for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech. The company made little clinical progress and, in fact, one of the major data readouts it released was not

Investors in biotechnology company Viking Therapeutics (NASDAQ: VKTX) had a rollercoaster ride in 2025, driven by clinical trial data, or rather, the perception of the clinical trial data. Let's

Greg Zante, the chief financial officer of Viking Therapeutics (NASDAQ:VKTX), reported the direct sale of 57,661 shares of the biotech in multiple open-market transactions valued at $1.9 million

On a planet whose surface consists mostly of water, it's not a surprise to see different companies cashing in on transporting guests across the many oceans, seas, and rivers. Carnival Corp. (NYSE: